Roche: Antibody cocktail reduces symptomatic COVID infections by 81%

Monday, 12. April 2021 07:25

F. Hoffmann-La Roche AG announced on Monday that its antibody cocktail of casirivimab and imdevimab reduced the risk of symptomatic infections by 81%. Additionally, in those that were symptomatic when given the cocktail the virus lasted one week, compared to three weeks with the placebo group.

Roche also said that their cocktail is 31% effective in reducing the risk of asymptomatic patients progressing to symptomatic. Levi Garraway, Roche's Chief Medical Officer, stated that "today’s data confirm the potential dual value of casirivimab and imdevimab to reduce household COVID-19 infections and to decrease the disease burden in those who do become infected, when given as a subcutaneous option," adding that despite vaccinations there is "critical unmet need worldwide to prevent infections and provide immediate protection from COVID-19 between close contacts."

Roche's clinical trials have previously shown that the antibody cocktail is 70% efficient in reducing the risk of hospitalization and death in those infected with the coronavirus. Roche and Regeneron Pharmaceuticals stated they will ask the Food and Drug Administration for the cocktail to be used as a preventative COVID-19 treatment.

Related Links: Roche Holding
Breaking the News / OL